Interaction of Statins and Nondepolarizing Muscle Relaxants

Pain Clinical Trial

Official title:

Interaction of Statins and Nondepolarizing Muscle Relaxants

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02222519
• Other study ID #: 2014071801
• Status: Recruiting
• Phase: Phase 4
• First received: August 14, 2014
• Last updated: October 22, 2014
• Start date: October 2014
• Est. completion date: September 2015

Study information

• Verified date: October 2014
• Source: First Hospital of China Medical University
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Observational

Clinical Trial Summary

provide evidence for prevention or reduction muscle pain.

Description:

The purpose of this study is to determine interaction of statins and nondepolarizing muscle relaxant,In order to provide evidence for prevention or reduction muscle pain.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: September 2015
• Est. primary completion date: September 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients with American Society of Anesthesiologists physical status I-III

• Patients taking statins for at least 3 months and those who had never used statins were considered to be eligible

Exclusion Criteria:

• Orthopedic

• Spinal surgery

• Surgery involving extensive muscle manipulation

• History of liver and kidney failure

• Neuromuscular disease

• Susceptibility to or family history of malignant hyperthermia

• Extensive denervation of skeletal muscle

• Chronic pain syndromes

• Taking medications that might interact with the effect of rocuronium or serum myoglobin difficult intubation

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Muscle Hypotonia
• Pain

Intervention

Drug:
• Rocuronium
Rocuronium 0.6mg/kg iv single dose

Locations

Country	Name	City	State
China	China Medical University	Shenyang	Liaoning

Sponsors (1)

Lead Sponsor	Collaborator
Huang-wei LV

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	plasma myoglobin concentration		20 minutes after administration	No
Secondary	muscle pain		2 and 24 hours postoperatively	No
Secondary	serum potassium concentration		2 and 24 hours postoperatively	No
Secondary	plasma creatine phosphokinase concentration		2 and 24 hours postoperatively	No
Secondary	urine myoglobin and onset plus duration of succinylcholine block		2 and 24 hours postoperatively	No